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A B S T R A C T
We have adapted the methodology of Berry et al. (2012) for Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) treatments at
a ﬁxed source to imager distance (SID) based on the manufacturer’s through-air portal dose image prediction algorithm. In order to ﬁx the SID a correction factor was
introduced to account for the change in air gap between patient and imager. Commissioning data, collected with multiple ﬁeld sizes, solid water thicknesses and air
gaps, were acquired at 150 cm SID on the Varian aS1200 EPID. The method was veriﬁed using six IMRT and seven VMAT plans on up to three diﬀerent phantoms. The
method’s sensitivity and accuracy were investigated by introducing errors. A global 3%/3mm gamma was used to assess the diﬀerences between the predicted and
measured portal dose images. The eﬀect of a varying air gap on EPID signal was found to be signiﬁcant – varying by up to 30% with ﬁeld size, phantom thickness, and
air gap. All IMRT plans passed the 3%/3mm gamma criteria by more than 95% on the three phantoms. 23 of 24 arcs from the VMAT plans passed the 3%/3mm
gamma criteria by more than 95%. This method was found to be sensitive to a range of potential errors. The presented approach provides fast and accurate in-vivo
EPID dosimetry for IMRT and VMAT treatments and can potentially replace many pre-treatment veriﬁcations.
1. Introduction
Intensity Modulated Radiotherapy (IMRT) and Volumetric
Modulated Arc Therapy (VMAT) enable the delivery of highly con-
formal and uniform dose distributions to planning target volume (PTV)
whilst sparing organs at risk (OARs) [1]. While this enhanced delivery
capability has been shown to be advantageous with respect to im-
proving patient outcome [2,3], it does introduce new challenges for the
quality assurance (QA) of treatments in term of additional linac QA as
well as patient-speciﬁc QA, which is recommended to be carried out
prior to, or within the ﬁrst few fractions of treatment [4,5]. In vivo
dosimetry is a form of patient-speciﬁc QA that oﬀers certain advantages
over pre-treatment QA, namely that it actually veriﬁes what is really of
interest: the dose delivered to the patient. Within 4 years at the Neth-
erland Institute of Cancer Research, more than 4000 plans were veriﬁed
using an in-vivo dosimetry system. Of the 17 serious errors detected, 9
would not have been detected with pre-treatment veriﬁcation [6]. The
same conclusion was obtained from another study by the same institute
carried out on more than 15,000 plans. 35 serious errors were detected
that would not have been detected with pre-treatment veriﬁcation due
to mainly changes in patients anatomy [7].
EPID dosimetry can oﬀer advantages in terms of the ease and speed
with which in vivo dosimetry can be performed, the extra information
aﬀorded by sampling the entire radiation ﬁeld rather than just a single
point (as by using thermo-luminescent detectors (TLDs) or diodes), and
the additional scope it oﬀers for detecting changes in patient anatomy
[8–10]. EPID dosimetry can be performed in many diﬀerent ways, an
overview of which is given in the literature review by Van Elmpt et al.
[11]. Within the subcategory of in vivo EPID dosimetry several im-
plementations have been developed each of which veriﬁes the dose to
the patient in diﬀerent ways. Several in-vivo EPID software solutions
have been commercially available recently and have been assessed in a
number of studies [12,13]. However, the solutions thus far have mainly
been developed in house by academic centres, resulting in a wide
variety of methodologies. These methodologies can be divided into: a
point dose veriﬁcation in the patient, 2D transit dose veriﬁcation at the
level of the EPID, 2D transit dose veriﬁcation in a plane in the patient or
3D transit dose veriﬁcation in the patient [14–19]. A recent study by
Bedford et al. (2017) investigated the agreement between the forward
and back-projection transit EPID dosimetry for prostate radiotherapy.
They found a fairly similar response from both methods and they
concluded that both of them can be used to verify the dose delivered to
the patient [20].
Van Elmpt et al. (2005) developed a system that predicted a transit
portal dose image using a through air portal dose image and the radi-
ological thickness of the path of the beam through the patient [21].
Berry et al. (2012) used a similar technique, but rather than using a
measured through air portal dose image, they used the image predicted
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by the Varian Portal Dosimetry software, which is based on the work of
Van Esch et al. [15,22]. However, in their model, a ﬁxed air gap of
35 cm was used between the phantom exit and EPID. The ﬁxed air gap
causes several problems. Firstly, it increases the treatment time for each
patient as the EPID needs to be moved for each beam in order to keep a
constant air gap which has several consequences including increased
risk of intra-fraction motions and reduced patient throughput. Sec-
ondly, it increases the generation time of the portal dose images
through air since each beam requires a veriﬁcation plan with a diﬀerent
source to imager distance (SID) to be created in the Eclipse treatment
planning system (TPS). Finally, it is not suitable for VMAT treatments as
EPID needs to be at a ﬁxed SID while the gantry rotates. Another lim-
itation of the original methodology used by Berry et al. was that they
did not include the couch model in their calculations, and consequently
reported a decrease in the mean gamma pass rate for ﬁelds that transit
the couch [23].
The aim of this work is to extend the methodology of Berry et al.
(2012) to be used for both IMRT with a ﬁxed SID and VMAT treatments.
This is achieved by introducing a correction factor which takes into
account the change in air gap between the patient exit and EPID for a
ﬁxed SID. To improve the accuracy of the system, the couch model was
included in our calculation to take into account the couch attenuation
at any gantry angle. In addition, a new approach to calculate IMRT and
VMAT equivalent square ﬁeld size is presented.
2. Materials and methods
2.1. Equipment
Portal dose images were delivered on a Varian TrueBeam linac
which is equipped with the Varian portal imager aS1200. This imager
has a sensitive area covering a 40× 40 cm2 ﬁeld size at a 100 cm SID
and high resolution (1190×1190 pixels) in the dosimetry mode. In
addition, it has a backscatter shield to remove the eﬀect of uneven
backscatter from the support arm [24]. Portal dose images were ac-
quired at dose rate up to 600MU/min (the max dose rate for 6MV
beam) on this machine.
The imager was calibrated according to the manufacturer's re-
commendation and the central pixel value calibrated to equal 0.444 CU
(calibrated unit) when irradiated with 100MU and a 10× 10 cm2 ﬁeld
at 150 cm SID. All measured portal dose images (mIs) in our experi-
ments were acquired at a 150 cm SID. Three phantoms were used in the
veriﬁcation: A 30×30×19 cm3 water-equivalent “solid water (SW)”
phantom, the RT01 phantom and the BrainLab pelvis phantom
(BrainLab Medical Systems, Westchester, IL) (see Fig. 1) [25]. In ad-
dition, slabs of tissue-equivalent materials (water, bone and lung) were
used to create phantoms with a range of complexities in order to test the
accuracy of the presented model.
The predicted portal dose images through air (pIsair) were created
using Eclipse v13.7. For an in-depth description of how pIsair are cal-
culated, see the paper by Van Esch et al. [22]. The RT plan, RT
structure, CT images and pIsair are imported to in-house software
written in Python v3.5.1 in order to calculate the predicted images
through patient (pIsp).
2.2. Predicted images through patient model
The pIp for any ﬁeld size (FS), thickness (t), air gap (g) and ﬁxed SID
can be calculated from the pIsair at any position (x, y) on the EPID using
the following equation:
= ∙ ∙ ∙pI pI T x y FS t OAR x y t G x y FS t g( , , , ) ( , , ) ( , , , , )p air (1)
Each of the terms in Eq. (1) is brieﬂy described in Table 1 below.
2.2.1. Transmission correction factor model
In the implementation used by Berry et al. (2012), two terms were
used to account for the two primary causes of attenuation of the beam
through the phantom: the attenuation of the primary beam, which was
modelled in narrow beam conditions using Monte Carlo (MC) simula-
tions, and the eﬀect of scattered and secondary radiation, which was
empirically derived by measuring the EPID response for several ﬁeld
sizes and SW block thicknesses [15]. In this work, both terms are
combined into one empirically derived correction factor dependent on
attenuator thickness and ﬁeld size. A series of images were acquired
with the EPID for diﬀerent ﬁeld sizes and thicknesses of SW blocks to
determine the equation that deﬁnes this correction factor. The data
were ﬁtted using a nonlinear least squares method to the following
equation:
=
+
− −
T t FS A FS e C FS e
S FS
( , ) ( ) ( )
(0, )
B FS t D FS t( ) ( )
(2)
where = +−A FS a e a( ) a FS1 32 , =B FS b FS( ) b1 2, = +−C FS c e c( ) c FS1 32 ,
=D FS d( ) FS1 d2.
S FS(0, ) is the mean signal in the 4× 4 pixels at the EPID centre
produced by the beam with no attenuation for a given ﬁeld size.
a a a b b c c c d d, , , , , , , , ,1 2 3 1 2 1 2 3 1 2 are empirically determined ﬁtting para-
meters. Table 2 summarises the commissioning measurements per-
formed to determine the T factor. The model was then veriﬁed with a
mix of ﬁeld sizes and SW thicknesses.
Fig. 1. Phantoms used to verify our method: (a) a 19 cm solid water phantom, (b) the RT01 phantom and (c) the BrainLab pelvis phantom.
Table 1
A brief summary of each term in Eq. (1).
Parameter Description
T Transmission factor which takes into account the attenuation of the
beam through the phantom
OAR The oﬀ-axis pixel response function, that accounts for the fact that
the oﬀ axis spectrum of the incident beam varies as a function of
radial distance from the central axis
G The air gap factor which corrects the EPID response due to change in
the distance between the patient exit and EPID
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2.2.2. Oﬀ-axis pixel response factor model
This correction factor is derived empirically, using a similar set of
data as for the T correction factor, but with only a ﬁeld size that fully
covers the EPID at 150 cm SID (27× 27 cm2). A third-degree poly-
nomial is used to ﬁt the OAR factor for each individual pixel as a
function of the attenuator thickness as described in the following
equation:
= + + +OAR i j α i j t i j α i j t i j α i j t i j α i j( , ) ( , ) ( , ) ( , ) ( , ) ( , ) ( , ) ( , )1 3 2 2 3 4
(3)
For a given pixel at the ith row and jth column
α i j α i j α i j α i j( , ), ( , ), ( , ), ( , )1 2 3 4 are empirically determined ﬁtting
parameters and t i j( , ) is the equivalent radiological path length traced
through the CT scan to the pixel.
Table 3 summarises the commissioning measurements performed to
determine the OAR factor.
2.2.3. Air gap correction factor model
A series of portal dose images were acquired with the EPID for
diﬀerent ﬁeld sizes, thicknesses of SW blocks and air gaps to determine
the correct model for this factor. In this work, the G factor is divided
into two terms:
=G x y t FS g G t FS g G x y g( , , , , ) ( , , ) ( , , )c o (4)
where G t FS g( , , )c is the air gap factor at the centre region (the 4× 4
pixels at EPID centre) of the EPID which is a function of thickness, ﬁeld
size and air gap.G x y g( , , )o is the air gap oﬀ-axis pixel response function
which takes into account the change in oﬀ-axis pixel response due to
the change in air gap distance. Both factors were normalised to a 40 cm
air gap. A multi-dimensional look-up table to interpolate between ﬁeld
sizes, thicknesses, and air gaps is used to model the Gc factor. The Go
factor was ﬁtted using a nonlinear least squares method to the following
equation:
=
−G x y g e( , , )o g x yΔ( ).Ω( , ) (5)
where: = − + − +g β g g β g g βΔ( ) ( ) ( )1 0 2 2 0 3, =
+x yΩ( , ) γ x yγ
( )1 2 2
2
.
where β β β γ γ, , , ,1 2 3 1 2are the empirically determined ﬁtting para-
meters and g0 is the default air gap at which the other correction factors
were modelled. In this work, =g cm400 . Table 4 summarises the com-
missioning measurements used to determine the G factor.
2.2.4. The equivalent thickness map
In order to predict the eﬀect of patient (phantom) attenuation on
pIair, information about the radiological path length for each photon
beam arriving at the EPID is required. The patient CT scan is used along
with a calibration table which converts from Hounsﬁeld Units (HU) to
electron density to calculate electron density at each voxel in the CT
scan. The body outline from the structure set is used to restrict the
calculated voxels to just those within the body. The couch structure,
generated in the Eclipse TPS, is also included in the calculation so that
the attenuation through the couch at any gantry angle is included. The
radiological path length is then calculated for each ray arriving at a
pixel at the EPID using the method reported by Siddon [26]. The ray
tracing algorithm was veriﬁed using virtual phantoms with known
geometries and densities as well as comparing the equivalent thickness
at the central axis for each veriﬁcation plan to that obtained from
Eclipse TPS. The calculated equivalent thicknesses were found to agree
with those calculated in Eclipse to within±1mm.
2.2.5. Equivalent square ﬁeld size for dynamic ﬁelds
To assess the impact of both the collimator and MLC positions on the
estimation of the equivalent square ﬁeld size, we investigated if the
equivalent square ﬁeld size for a given dynamic ﬁeld can be calculated
from only the ﬁeld formed by X and Y secondary collimators. Several
dynamic ﬁelds with the same X and Y secondary collimator (i.e.
10× 10 cm2) opening but diﬀerent ﬂuence map were delivered
through a 20 cm thick SW phantom at three diﬀerent air gaps: 20, 30
and 40 cm. Fig. 2 shows the ﬂuence map for each dynamic ﬁeld. It was
found that the correction factors depend on both total ﬂuence and open
area and not only on the X and Y collimator size. The equivalent square
ﬁeld size FS, which gives the best agreement with our measurements,
was found to be calculated using the following empirical equation:
=FS FS
A
AOF
f
OF (6)
where FSOF is the equivalent square ﬁeld size calculated from X and Y
collimators, Af is the area in the ﬁeld where the ﬂuence is larger than
zero, and AOF is the area within the ﬁeld formed by X and Y collimators.
2.3. Predicted images through patient model veriﬁcation
Six IMRT plans and seven VMAT plans were used to verify the
presented method. The IMRT plans were clinical prostate and seminal
vesicle plans; two were planned according to the CHHiP trial protocol,
two to the PACE protocol, and two according to the pre-CHHiP clinical
standard at RMH [27,28]. The VMAT plans consisted of prostate bed
(n= 2), prostate and nodes (n= 2), larynx bed (n=2), and vagina
(n= 1) plans. Each plan was delivered on up to three diﬀerent phan-
toms described in Section 2.1. In total, 15 IMRT ﬁelds were delivered to
the RT01 phantom, 15 IMRT ﬁelds and 12 VMAT arcs were delivered to
the 19 cm solid water phantom, and 30 IMRT ﬁelds and 12 VMAT arcs
were delivered to the BrainLab pelvis phantom. pIsp and mIs were
compared using a global 3%/3mm gamma evaluation with 10% dose
threshold as it is the most common gamma criteria used in dosimetric
QA [29].
In addition, pIsp and mIs were compared using a local 2%/2mm
Gamma criteria to test the sensitivity of the system [29].
All plans used were independently veriﬁed using PTW OCTAVIUS
1500 ionisation chamber array (PTW, Freiburg, Germany) and/or
Varian pre-treatment veriﬁcation (Portal Dosimetry) software. All plans
passed the local 3%/3mm gamma evaluation by more than 98% on the
PTW array and by more than 99% on Varian pre-treatment veriﬁcation
Table 2
The commissioning measurements used to model the T factor.
Field size (cm2) Solid water
thickness (cm)
Air gap
(cm)
Gantry
(deg)
MUs
3×3, 5× 5, 8×8,
10× 10, 15× 15,
20× 20, 25× 25
0, 5, 10, 15, 20,
25, 30, 35, 40
40 270 100
Table 3
The commissioning measurements used to model the OAR factor.
Field size (cm2) Slabs thickness (cm) Air Gap
(cm)
Gantry (deg) Mus
27×27 0, 1, 2, 3, 5, 10, 15, 20, 25,
30, 35, 40
40 0 100
Table 4
The acquisition parameters used to model the G factor.
Field size (cm2) Slabs thickness
(cm)
Air gap (cm) Gantry
(deg)
MUs
5×5, 10× 10,
15× 15, 20× 20
0, 10, 15, 20, 25,
30, 35, 40
20, 25, 30, 35,
40, (45, 50,
55)*
0 100
* If possible due to machine interlock for large air gaps and solid water
blocks.
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software.
2.3.1. The eﬀect of heterogeneity
To investigate the ability of our model to predict accurate portal
dose images in the presence of heterogeneities, an anterior IMRT ﬁeld
from one of the six prostate plans was delivered on several phantoms
(shown in Fig. 3). These phantoms were made of tissue-equivalent
materials; water (WT1, relative electron density= 1.0), cortical bone
(SB5, relative electron density= 1.73) and lung (LN10, relative elec-
tron density= 0.3) [30] with a range of complexities similar to what
was presented by the work of Berry et al. [15].
The following geometries and material conﬁgurations were
Fig. 2. The ﬂuence maps used to determine the equivalent square ﬁeld size for a dynamic ﬁeld.
Fig. 3. Diagrams of the slab phantoms used to test our model using a range of homogeneous and inhomogeneous geometries, with materials of varying electron
densities. a, c, d: A ﬁeld pointing directly at a 10 cm thick slab of WT1, 5 cm thick slab of SB5, 5.5 cm thick slab of LN10, respectively. b: A ﬁeld pointing directly and
beam passing through part of a 10 cm thick slab of WT1. e, f: A ﬁeld pointing directly and passing through multiple materials (WT1-LN10-WT1 and WT1-SB5-WT1,
respectively) with tissue boundaries along the ray path. g, h, i: A ﬁeld pointing directly and passing through multiple materials (WT1-[WT1-SB5]-WT1, WT1-[WT1-
LN10]-WT1 and WT1-[SB5-LN10]-WT1, respectively) with tissue boundaries along the ray path and perpendicular to the treatment ﬁeld.
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measured with the ﬁeld pointing directly at the phantom: single ma-
terials (Fig. 3a–d), single material with a beam passing through part of
the phantom only (Fig. 3b), multiple materials with tissue boundaries
along the ray path (Fig. 3b–f), multiple materials with tissue boundaries
both along the ray path and perpendicular to the treatment ﬁeld
(Fig. 3g–i)
2.4. Model sensitivity
2.4.1. Error detection
In order to test the sensitivity of our model to detect dose delivery
errors in the patient, several types of errors were deliberately in-
troduced either into the plan itself or the phantom setup. This was done
using a single IMRT veriﬁcation plan and followed an approach similar
to that of Bedford et al. [14]. The pIsp for the unaltered plan and setup
were compared to the mIs for the delivery containing the errors, to test
whether the dose discrepancy is greater than that observed for the
unaltered IMRT plan and therefore determine whether the error can
actually be detected.
The deliberate errors were all introduced to a prostate IMRT plan,
created in accordance with the CHHiP trial protocol. The error plans
were all delivered to the BrainLab pelvis phantom apart from in the
case of the change in phantom size, which was done using SW blocks.
The errors introduced were:
1. Dose errors: The number of monitor units for all ﬁelds in the plan
was altered by −5%, +1%, +3%, +5% and +10%, creating ﬁve
new plans with deliberate errors in. All other aspects of the plan
were kept the same.
2. Gantry angle error: Two plans were created, identical to the original
plan on the BrainLab pelvis phantom, except with gantry angle
oﬀsets of +5° and +10° introduced.
3. Patient set-up errors: One ﬁeld from the original plan (the left
anterior oblique ﬁeld, at a gantry angle of 35°) was delivered to the
BrainLab pelvis phantom, but with the phantom oﬀset by 0.5 cm,
1 cm, 1.5 cm and 2 cm laterally towards the patient’s right, and by
the same oﬀsets in the anterior direction, resulting in 8 deliveries of
one ﬁeld.
4. Change in phantom size: For this sensitivity test, the posterior ﬁeld
(180°) from the original plan was delivered to the CT scanned 19 cm
solid water block, with 0.5 cm, 1 cm, 2 cm and 3 cm of solid water
added on top; only the posterior ﬁeld was measured to save time, as
this was the ﬁeld that would be most aﬀected by a change in depth
of the phantom.
5. MLC errors: new versions of the original plan were created with
MLC errors introduced by altering the MLC plan ﬁle using a python
script. The MLC ﬁles were then imported back into Eclipse, and the
plan was calculated again using the new MLC positions. The type of
MLC errors and the ﬁelds which they were applied to is detailed in
Table 5.
3. Results
3.1. Transmission correction factor
The T factor was ﬁtted successfully using Eq. (2). The R2 value of the
ﬁtted equation was found to be 0.9998. The ﬁtting parameters are listed
in Table 6. Fig. 4 shows the measured and modelled T factor as a
function of SW thickness for several ﬁeld sizes. A comparison of the
measured and modelled T factors for several ﬁeld sizes and SW thick-
nesses is shown on Table 7.
3.2. Oﬀ-axis pixel response factor
All measured and modelled OAR model images passed the 0.5%/
0.5 mm 2D gamma by 100%. Fig. 5 shows the measured and modelled
OAR factors as a function of SW thickness at diﬀerent positions on the
EPID.
3.3. Air gap correction factor
Fig. 6a shows the measured and modelled Gc factors for a
15× 15 cm2 ﬁeld size as a function of SW thickness at diﬀerent air
gaps. Fig. 6b shows Gc factor for 30 cm solid water thickness as a
function of ﬁeld size for diﬀerent air gaps.
A comparison of the measured and modelled Gc factors for several
ﬁeld sizes, SW thicknesses and air gaps is shown in Table 8.
Table 5
The MLC errors that were deliberately introduced into each ﬁeld of one of IMRT
plans in order to test the sensitivity of portal dosimetry to diﬀerent types of
MLC error.
Error Field (Gantry angle
[deg])
MLC error
E1 All ﬁelds Both banks shifted in the same direction by 5mm
E2 POST (180°) Shift both leaf banks in by 2mm
E3 LPO (100°) Shift the leaves of bank B that are within the ﬁeld
in by 5mm
E4 LAO (35°) Shift one leaf in bank A that is close to the centre
of the ﬁeld in by 1 cm
E5 RAO (325°) Open all leaf pairs that are within the ﬁeld out by
5mm
E6 RPO (260°) Shift four leaves from bank A at the superior edge
of the treatment ﬁeld by 1 cm
Table 6
T factor ﬁtting parameters.
= −a 0.95801 =a 0.01852 =a 0.95293 =b 0.41431 = −b 0.70292
= −c 50.27171 = −c 0.00022 =c 50.66473 =d 0.05481 = −d 0.16752
Fig. 4. The measured (circles) and modelled (lines) T factors as a function of
solid water thicknesses for diﬀerent ﬁeld sizes.
Table 7
The modelled and measured T factors for diﬀerent ﬁeld sizes and SW thick-
nesses.
Field Size (cm) Thickness (cm) Measured (CU) Modelled (CU) Diﬀ (%)
25× 25 2.84 0.419 0.4191 0.0
7× 18 17 0.187 0.1865 −0.3
13× 13 17 0.197 0.1968 −0.1
7× 14 23.84 0.134 0.1337 −0.2
15× 15 0.84 0.438 0.4385 0.1
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Fig. 7a and b show theGo factor along the x-axis at 30 cm air gap for
a 15×15 cm2 ﬁeld size and diﬀerent SW thicknesses and 20 cm solid
water thickness and diﬀerent ﬁeld sizes, respectively. Fig. 7c shows the
measured and modelledGofactor along the x-axis as a function of air gap
for a 20×20 cm2 ﬁeld size and 20 cm SW thickness. Fig. 7d shows the
diﬀerence between the modelled and measured Go factor for diﬀerent
air gaps. Table 9 lists the ﬁtting parameters used to ﬁt Eq. (5). The R2
value of the ﬁtted equation was found to be 0.9994.
3.4. Veriﬁcation results
3.4.1. IMRT plans
All IMRT ﬁelds (60 ﬁelds in total) passed the 3%/3mm gamma
criteria by more than 95%. The average gamma pass rate was
99.8 ± 0.3(1SD), 99.9 ± 0.3(1SD) and 99.3 ± 1.2(1SD) for 19 cm
SW, RT01 and BrainLab pelvis phantoms, respectively. Fig. 8 shows a
histogram of gamma pass rate for all IMRT ﬁelds on the three phan-
toms. The average gamma pass rate for beams which do and do not pass
through the couch was found to be the same (99.6 ± 0.9(1SD)). 45 of
60 ﬁelds passed the local 2%/2mm gamma criteria by more than 95%.
The overall global 3%/3mm and local 2%/2mm gamma pass rate and
mean gamma for all IMRT ﬁelds are listed in Table 10.
3.4.2. VMAT plans
For VMAT plans, 23 of the 24 arcs passed the 3%/3mm gamma
criteria by more than 95%. However, the 3%/3mm gamma pass rate of
the failed arc was 94.6%. The mean 3%/3mm gamma pass rate was
98.7 ± 1.8(1SD) and 98.9 ± 1.5(1SD) for the 19 cm SW and BrainLab
pelvis phantoms, respectively. Fig. 9 shows a histogram of gamma pass
rate for all VMAT ﬁelds on the 19 cm SW and BrainLab pelvis phantoms.
None of the VMAT plans passed the local 2%/2mm gamma criteria
by more than 95%. The overall global 3%/3mm and local 2%/2mm
gamma pass rate and mean gamma for all VMAT arcs are listed in
Table 10. Fig. 10 shows the pIp and mIs images and global 3%/3mm and
local 2%/2mm gamma maps for a VMAT ﬁeld delivered on the
BrainLab pelvis phantom.
3.4.3. The eﬀect of heterogeneity
All beams, delivered on phantoms shown in Fig. 3, passed the 3%/
3mm gamma criteria by more than 99.5% (see Fig. 1 in the
Supplementary material).
3.5. Model sensitivity
3.5.1. Error detection
Table 11 shows the 3%/3mm gamma pass rate for the plans with
errors deliberately introduced that were delivered on the BrainLab
pelvis phantom.
Table 12 shows the 3%/3mm gamma pass rate and mean gamma,
mean dose diﬀerence and the dose diﬀerence at the centre of the EPID
between the measured and predicted images for errors plans delivered
on a 19 cm SW phantom.
4. Discussion
As can be seen in Fig. 4, the modelled T factor was in a good
agreement with measured values. The diﬀerence between the measured
and modelled T factor for diﬀerent ﬁeld sizes and SW thicknesses was
Fig. 5. The measured (circle) and modelled (line) OAR factors as a function of
solid water thicknesses at diﬀerent locations on the EPID. Note the error bars
illustrate a 0.5% diﬀerence in OAR value at each point.
Fig. 6. The measured (circle) and modelled (line) Gc factor at diﬀerent air gaps as (a) a function of attenuator thickness for a 15×15 cm2 ﬁeld size and (b) as a
function of ﬁeld size for a 30 cm solid water thickness.
Table 8
The modelled and measured Gc factors for diﬀerent ﬁeld sizes, SW thicknesses
and air gaps.
FS (cm2) t (cm) g (cm) Measured Modelled Diﬀ (%)
13 20.84 35 1.024 1.024 0.0
13 20.84 30 1.054 1.052 −0.2
13 20.84 20 1.151 1.149 −0.1
13 20.84 37 1.012 1.014 0.2
7.9 30.46 35 1.019 1.013 −0.6
7.9 30.46 30 1.029 1.032 0.4
10 9.34 35 1.011 1.010 −0.1
10 9.34 30 1.022 1.022 0.0
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found to be less than 0.5% as seen Table 7. Berry et al. (2012) used two
terms to model this factor and carried out several MC simulations to
calculate the mass attenuation factor for a 6 MV photon beam [15].
However, we found that using one term to model this factor was suf-
ﬁcient and easier to implement since no MC simulations are required.
With regards to OAR factor, the third-degree polynomial model at
each individual pixel was found to accurately ﬁt this factor (Fig. 5). All
commissioning images passed by 100% the 0.5%/0.5 mm 2D gamma
evaluation. The third-degree degree polynomial model was found to
give better agreement in our work compared with the Gaussian model
introduced by Berry et al. (2012). This diﬀerence could be due to the
Fig. 7. The measured Go factor at a 30 cm air gap for (a) a 15×15 cm2 ﬁeld size and diﬀerent thickness and (b) for a 20 cm solid water thickness and diﬀerent ﬁeld
sizes. (c) The measured (dashed line) and modelled (solid line) Go factor along the x-axis for a 20×20 cm2 ﬁeld size, 20 cm SW thickness and several air gaps. (d) The
percentage diﬀerence between the measured and modelled Go factor along the x-axis for diﬀerent air gaps.
Table 9
The ﬁtting parameters of Go factor.
=
−β 7.5902 101 8 =β 1.02112 =β 40.12473 = −γ 28.68661 =γ 26.77422
< 95% 95% -96% 96% - 97% 97% - 98% 98% - 99% 99% - 100%
RT01 0 0 0 0 6.7 93.3
SW19cm 0 0 0 0 6.7 93.3
Pelvis 0 3.3 3.3 3.3 16.7 73.4
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Fig. 8. Gamma pass rate histogram for IMRT ﬁelds delivered on the three phantoms.
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Table 10
The overall global 3%/3mm and local 2%/2mm gamma pass rate and mean gamma for all IMRT and VMAT plans.
Global 3%/3mm gamma Local 2%/2mm Gamma
Pass rate [%] Mean gamma Pass rate [%] Mean gamma
IMRT 99.6 ± 0.9(1SD) 0.22 ± 0.07(1SD) 96.1 ± 5.5(1SD) 0.33 ± 0.11(1SD)
VMAT 98.8 ± 1.7(1SD) 0.30 ± 0.05(1SD) 84.5 ± 6.7(1SD) 0.82 ± 0.32(1SD)
< 95% 95% -96% 96% - 97% 97% - 98% 98% - 99%
99% -
100%
SW19cm 7.1 7.1 0.0 7.1 0.0 64.3
Pelvis 0.0 14.3 0.0 0.0 14.3 57.1
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Fig. 9. 3%/3mm gamma pass rate histogram for VMAT ﬁelds delivered on the 19 cm SW and BrainLab phantoms.
Fig. 10. The (a) Measured, (b) Predicted, (c) global 3%/3mm gamma map and (d) local 2%/2mm gamma map for a VMAT ﬁeld delivered on the BrainLab pelvis
phantom.
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EPID model (aS1000) that they used in their study. In addition, Berry
et al. used a ﬁeld size speciﬁc backscatter correction that was pre-
viously developed for portal dosimetry by the same group [31]. In this
work, no backscatter correction was used with the aS1200 since this
EPID model has backscatter shield to remove the eﬀect of uneven
backscatter from the support arm [24].
It can be found from Fig. 6a and b that the eﬀect of air gap is not
negligible and the EPID signal can vary by up to 30% for the smallest air
gap and largest ﬁeld size and SW thickness. The Gc factor was found to
increase as the ﬁeld size and thickness increases and as the air gap
decreases. This could be due to the increase in secondary (scattered)
photons that reach the EPID. We used a multi-dimensional look-up
table to calculate theGc factor for a given ﬁeld size, attenuator thickness
and air gap as no ﬁtting equation was found to model this factor ac-
curately. The diﬀerence between the measured and calculated values
for several images with a range of ﬁeld sizes, SW thicknesses and air
gaps was found to be less than 1% as seen in Table 8.
As seen in Fig. 7a–c, the Go factor is relatively independent of ﬁeld
size and thickness, and is only aﬀected by distance between the patient
exit and EPID. Eq. (5) was found to accurately model this factor with R2
equal to 0.9994 as can be seen in Fig. 7c. The diﬀerence between the
measured and modelled factor was found to be less than 1% at any
point as seen in Fig. 7d.
Even though the eﬀect of air gap on EPID central axis dose was
studied by Talamonti et al. (2006) for pre-treatment IMRT veriﬁcation
[32], to the authors' knowledge, no one has introduced a model to
correct the EPID in-axis and oﬀ-axis pixel response due to the change in
the air gap between the patient and the imager.
The introduced model veriﬁed successfully for several IMRT and RA
plans on up to three diﬀerent phantoms. Most IMRT and RA ﬁelds
passed the 3%/3mm gamma criteria by more than 99% as can be seen
in Figs. 8 and 9 which is similar or superior to results published in
previous studies [14,15,33].
Berry et al. (2014) evaluated their model on 11 patients. They found
that the average 5%/3mm gamma pass rate was increased from 89.1%
to 95.7% by excluding all beams that interfere with the couch [23].
Since the couch structure was included in our model, no diﬀerence was
noticed in gamma pass rate between beams that interfere and do not
interfere with the couch. Therefore, the evaluation of the portal dose
images in our model should not be inﬂuenced by beams transmission
through the couch.
In order to determine the speciﬁcity and sensitivity of the system we
both introduced deliberate errors and varied the gamma criteria. The
high failure rate with a 2%/2mm gamma criteria (see Sections 3.4.1
and 3.4.2), when no deliberate errors were presented, means that the
speciﬁcity at this gamma criteria is too low for the system to be clini-
cally useful. At 3%/3mm, the speciﬁcity is suﬃcient for the test to be
useable. The sensitivity at this level is discussed below. The low spe-
ciﬁcity of the system at 2% 2mm gamma may be due to our not ac-
counting for higher-order scattering components [34]. In addition, the
eﬀect of penumbra and inter-leaf leakage is more pronounced in the
highly modulated treatments such as VMAT treatments [35]. It may be
possible to improve the accuracy of the system by taking further mea-
surements in order to produce a scatter kernel that, when convolved
with the predicted image, will improve agreement with measurements.
However, the 3% 3mm gamma criteria used compares favourably to
other published work. For example, Bedford et al. (2014) reported an
average 3%/3mm global gamma pass rate from 9 VMAT plans equals to
93.7 ± 3.0 [14]. In addition, the 3%/3mm gamma pass rate in our
method is considerably more than the action level of 90% per treatment
ﬁeld that was recommended in AAPM TG-119 for pre-treatment ver-
iﬁcation [36]. The diﬀering patterns of failure for diﬀerent beams
shown in Table 11, discussed in more detail below, demonstrates that
the failures are not due to systematic high or low predictions.
The predicted portal dose images for IMRT ﬁelds through diﬀerent
heterogeneous phantoms can be calculated accurately by our method,
achieving 3%/3mm gamma pass rate of more than 99.5% on all the
phantoms tested, as shown in Fig. 3. The geometries were simple, but
featured large discontinuities and materials with diﬀerent electron
densities. Diagram b in Fig. 3 indicates that the presented method could
be used for treatments where part of the ﬁeld extends beyond the pa-
tient (e.g. breast treatments).
From the results reported in Table 11, the introduced method
should be sensitive to dosimetric errors, the level of which is dependent
on the gamma criteria used. The higher the dose criteria, the less sen-
sitive the method will be to dose errors, as expected. Increasing the MUs
by more than 3% caused all ﬁelds to have passing rates at 3%/3mm
gamma criteria of less than 95%. These results agreed with the results
reported by Bedford et al. (2014) as all plans in their study fail the
gamma evaluation when they increase the number of MUs by 10% [14].
The results in Table 11 demonstrate that in principle, our method
should be sensitive to gantry angle errors, as the passing rates for some
of the ﬁelds delivered in the prostate plans, for both 5° and 10° shifts,
change markedly. For smaller angular rotations it is less likely to cause
Table 11
The 3%/3mm gamma pass rate for the error plans (see Section 2.4.1) that were
delivered on the BrainLab pelvis phantom.
Error 3%/3mm Gamma pass rate [%]
POST LPO LAO RAO RPO
No error (original plan) 99.9 98.2 100.0 99.9 98.1
Dose MUs increased by 1% 97.9 97.9 99.6 99.3 97.7
MUs increased by 3% 79.8 82.6 94.9 95.5 93.6
MUs increased by 5% 62.5 59.5 79.0 76.5 73.3
MUs increased by 10% 44.3 48.7 55.3 53.2 51.5
MUs decreased by 5% 97.9. 94.7 83.1 71.3 84.0
Gantry angle Oﬀset by +5° 97.8 99.0 94.1 91.3 98.6
Oﬀset by +10° 98.1 94.7 79.6 68.8 97.8
Set-up error Oﬀset by 0.5 cm (right) 100.0
Oﬀset by 1.0 cm (right) 100.0
Oﬀset by 1.5 cm (right) 99.7
Oﬀset by 2.0 cm (right) 97.8
Oﬀset by 0.5 cm (ant) 100.0
Oﬀset by 1.0 cm (ant) 100.0
Oﬀset by 1.5 cm (ant) 99.9
Oﬀset by 2.0 cm (ant) 99.6
MLC E1, Table 5 (not aligned) 61.3 51.4 46.4 62.8 59.0
E2, Table 5 79.5
E3, Table 5 47.9
E4, Table 5 98.3
E5, Table 5 14.5
E6, Table 5 94.3
Table 12
The gamma pass rate and mean gamma at 3%/3mm, mean dose diﬀerence and
the dose diﬀerence at the centre of the EPID between the measured and pre-
dicted images for errors plans delivered on a 19 cm SW phantom.
Error 3%/3mm Gamma
test
Mean dose
diﬀerence
[%]
Dose
diﬀerence at
the centre of
EPID [%]Pass
rate
[%]
Mean
Gamma
No Error (Original
plan)
100 0.12 0.3 0.7
Phantom size Increased
by 0.5 cm
100.0 0.26 −1.7 −1.6
Increased
by 1.0 cm
95.1 0.5 −2.9 −3.7
Increased
by 2.0 cm
48.2 1.03 −5.5 −8.1
Increased
by 3.0 cm
33.8 1.62 −7.8 −12.1
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a noticeable drop in passing rates, as the smaller the rotation from the
planned position the diﬀerence in the geometry that the beam transits.
The precise level of gantry error that will be detected will depend on
several factors including the speciﬁc patient anatomy and the location
of ﬁelds with respect to the anatomy. This shows that our method
should provide a way of detecting such an error, if a signiﬁcant one
were to occur.
The reported results from Table 11 show that, as might be expected,
set-up errors of up to 2 cm shifts of the patient in one direction do not
result in passing rates that would indicate that an error has occurred.
This result agrees with the results reported by Bedford et al. [14]. While
these set-up errors would result in signiﬁcant errors for the patient in
terms of dose localisation, the diﬀerences in the measured portal dose
images are small because the anatomy that the beam passes through, for
a prostate ﬁeld shifted by 2 cm relative to the patient, does not change
drastically. The sensitivity of the system to geometrical shifts will de-
pend on the anatomy of the patient, for example, the presence of sig-
niﬁcant inhomogeneities in and around the treatment ﬁeld, where
greater inhomogeneity increases the likelihood of detecting positional
errors. Our model was not intended to detect such set-up errors how-
ever, therefore the current protocols for treatment that are in place to
produce the correct set-up of the patient, such as kV imaging, should be
maintained in order to ensure this.
The results of the veriﬁcation measurements performed on plans
containing deliberate MLC errors, described in Table 11, demonstrate
that the current method is sensitive to a range of MLC errors. This is
consistent with the results reported by Bedford et al. [14]. The varied
MLC errors introduced to the individual ﬁelds (E2 to E6 in Table 5) all
produced distinct features in the gamma maps, making our model
sensitive to these errors. However, the MLC errors introduced are un-
likely to occur during treatment and more subtle MLC errors may not be
detected by the presented model at all.
Table 12 reports the results of the ﬁeld veriﬁcation measurements
performed with additional slabs of solid water added to the solid water
slab phantom to simulate changes to the patient outline: they demon-
strate that a change in water equivalent path length of 1 cm for an
original path length of roughly 20 cm should be detectable for IVED.
This type of error was not included in the study by Bedford et al. [14].
The precise thickness change that will result in a signiﬁcant drop in
the gamma passing rate will depend on the gamma criteria used, and
the original path length of the beam through the patient; the larger the
patient, the less changes in equivalent thickness will aﬀect the mea-
sured dose at the EPID. Although the gamma pass rate did not drop
enough to indicate an error for an additional 1 cm of SW, the error
could be indicated via changes in the mean gamma, mean dose diﬀer-
ence within the radiation ﬁeld and the dose diﬀerence at the centre of
the EPID between mIs and pIsp. Whilst patient weight changes can be
detected during CBCT scans, our system has the beneﬁt of being ap-
plicable to patients treated on a linac with an EPID, can be used for
every fraction and does not result in an additional dose to the patient.
Although in-vivo EPID dosimetry has the potential to detect in-
cidents which occur during treatments, many types of errors cannot be
detected such as incorrect prescription and contouring. Therefore, it
should be combined with other types of rules-based veriﬁcation [37].
Using a ﬁxed SID instead of a ﬁxed air gap reduces the total treat-
ment time since the EPID does not need to be moved for each beam to
maintain the same air gap. In addition, it reduces the generation time of
pIsair on Eclipse as only one veriﬁcation plan is required to generate the
pIsair .
The presented method is very simple to implement and can ﬂag a
number of signiﬁcant errors for further assessment (one of the re-
commendations in “Toward Safer Radiotherapy” [5]). It has the po-
tential to replace the pre-treatment veriﬁcation for treatment plans with
ﬁelds or arcs that can be ﬁt on the portal imager and do not have a large
couch rotation that restricts the use of the imager.
5. Conclusion
A model was introduced to perform in-vivo EPID dosimetry for
IMRT, at ﬁxed SID, and VMAT plans by adapting the methodology of
Berry et al. (2012). A new correction factor was introduced to account
for the change in air gap between the patient exit and EPID at each
radiation ﬁeld. To improve the sensitivity of the system, the couch
model was included in the calculation of the equivalent thickness map,
so the couch eﬀect does not inﬂuence the gamma results. The in-
troduced method was veriﬁed successfully on several IMRT and VMAT
plans. The majority of ﬁelds/arcs passed the 3%/3mm gamma criteria
by more than 95%. Furthermore, relative to the methodology of Berry
et al. (2012), our approach reduces the total treatment time and the
time to generate portal dose images through air in Eclipse. These factors
highlight the potential beneﬁt of such a system as part of the radio-
therapy pathway. Work is now in progress to evaluate the introduced
model in the clinic.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.ejmp.2018.07.010.
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